CORONA Remedies Acquires Wokadine® from Dr. Reddy's for ₹648 Cr
CORONA Remedies acquired Wokadine® from Dr. Reddy's for ₹648 crore. This is CORONA's fifth acquisition and enters them into the Povidone Iodine market. The deal is funded by internal accruals.
The acquisition of a #2 ranked brand in a ₹648 crore market is strategically important and expected to contribute to growth, but it is not a transformative event for the entire company.
The acquisition is viewed positively as it strengthens CORONA Remedies' product portfolio and market presence in a significant therapeutic area.
CORONA Remedies Limited has announced the strategic acquisition of the brand Wokadine® from Dr. Reddy’s Laboratories Ltd., effective March 30, 2026. This acquisition marks CORONA Remedies' fifth acquisition and its entry into the Povidone Iodine market in India, which is valued at ₹648 crore. Wokadine®, ranked #2 in its market segment, has a legacy of 46 years and is expected to strengthen CORONA's 'Healing' focus.
The acquisition will enable CORONA Remedies to penetrate deeper into targeted specialties and offer wider accessibility. The company plans to leverage its extensive distribution network to ensure the 14 SKUs of Wokadine® reach patients across all areas. The acquisition is funded through the company's internal accruals and cash.
Mr. Tejas Kothari, Vice President – Corporate Strategy & Business Development at CORONA Remedies, stated that the company continuously assesses growth opportunities to strengthen its brands. He believes this acquisition will enhance the existing product portfolio and deepen market penetration, confident in accelerating the brand's growth by building on strong relationships with healthcare professionals.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.